# US 2019/0316185 A1 · Systems and methods to detect rare mutations and copy number variation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316185 A1
- Document ID: US20190316185A1
- Status: Published application
- Kind: A1
- Application number: 16/389,680
- Filed: 2019-04-19
- Published: 2019-10-17
- Earliest claimed: 2012-09-04
- Assignees: Guardant Health, Inc.
- Applicants: Guardant Health, Inc.
- Inventors: AmirAli TALASAZ; HELMY ELTOUKHY; Stefanie Ann Ward MORTIMER
- Web page: https://patentgrep.com/patent/US20190316185A1

## CPC

- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6855: Ligating adaptors
- G16B 20/10: Ploidy or copy number detection
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 30/10: Sequence alignment; Homology search
- G16B 30/20: Sequence assembly
- C12Q 1/6869: Methods for sequencing
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.

## Claims

### Claim at position 1

-30. (canceled)

### Claim 31

A method for detecting a somatic genetic variant in cell-free deoxyribonucleic acid (cfDNA) molecules from a blood sample in a human subject, the method comprising:
(a) incubating between 1 nanogram (ng) to 100 ng of cfDNA molecules from the blood sample with at least an 80× molar excess of a set of molecular barcodes relative to the plurality of cfDNA molecules to generate tagged parent polynucleotides, said set of molecular barcodes comprising from 2 to 1,000,000 different molecular barcodes having respective molecule barcode sequences,
wherein the tagged parent polynucleotides comprises a cfDNA molecule and a respective molecular barcode pair attached thereon, the respective molecular barcode pair comprising a first molecular barcode attached to a first end of a cfDNA molecule from among the cfDNA molecules and a second molecular barcode attached to a second end of the cfDNA molecule,
wherein at least some of the tagged parent polynucleotides have an identical molecular barcode pair with respect to one another, and
wherein at least 20% of the cfDNA molecules are tagged with a corresponding molecular barcode pair;
(b) amplifying a plurality of the tagged parent polynucleotides to produce progeny polynucleotides;
(c) sequencing a subset of the progeny polynucleotides to produce a set of sequencing reads;
(d) mapping a plurality of the sequencing reads to one or more reference sequences to produce mapped sequenced reads;
(e) grouping a plurality of the mapped sequence reads into families based at least on the molecular barcode sequences of the molecular barcode pair and the beginning and end regions of the sequencing read that map to the one or more reference sequences, wherein a family comprises sequencing reads of progeny polynucleotides amplified from the same tagged parent polynucleotide; and
(f) detecting, from among the families, the presence or absence of one or more somatic genetic variants comprising a single nucleotide variation (SNV), an insertion or deletion (indel), a copy number variation (CNV), or a gene fusion.

### Claim 32 (depends on 31)

The method of claim 31, wherein the human subject has a cancer or is suspected of having a cancer.

### Claim 33 (depends on 31)

The method of claim 31, wherein the set of molecular barcodes are blunt-end ligated or sticky-end ligated to the cfDNA molecules.

### Claim 34 (depends on 31)

The method of claim 31, wherein at least 30% of the cfDNA molecules are tagged with a corresponding molecular barcode pair.

### Claim 35 (depends on 31)

The method of claim 31, wherein at least 40% of the cfDNA molecules are tagged with a corresponding molecular barcode pair.

### Claim 36 (depends on 31)

The method of claim 31, wherein incubating said blood sample comprising using at least a 100× molar excess of the set of molecular barcodes relative to the plurality of cfDNA molecules.

### Claim 37 (depends on 31)

The method of claim 31, wherein the set of molecular barcodes are part of adapter sequences.

### Claim 38 (depends on 31)

The method of claim 31, wherein the set of molecular barcodes comprises from 5 to 100 different molecular barcodes.

### Claim 39 (depends on 38)

The method of claim 38, wherein the molecular barcodes are double-stranded and are from 5 to 20 base pairs in length.

### Claim 40 (depends on 31)

The method of claim 31, further comprising selectively enriching the progeny polynucleotides for target regions associated with cancer.

### Claim 41 (depends on 31)

The method of claim 31, wherein the one or more reference sequences is a sequence of a human reference genome.

### Claim 42 (depends on 31)

The method of claim 31, further comprising filtering out sequencing reads that fail to meet a quality control threshold.

### Claim 43 (depends on 31)

The method of claim 31, wherein the beginning region comprises a start base position of the sequencing read and the end regions comprises a stop base position of the sequencing read.

### Claim 44 (depends on 31)

The method of claim 31, wherein detecting comprises generating a set of consensus sequences from among the sequence reads in the families.

### Claim 45 (depends on 44)

The method of claim 44, wherein a consensus sequence within the set corresponds to a sequence of a tagged parent polynucleotide.

### Claim 46 (depends on 44)

The method of claim 44, further comprising detecting the presence or absence of one or more somatic genetic variants in the set of consensus sequences compared with the one or more reference sequences.

### Claim 47 (depends on 31)

The method of claim 31, wherein detecting comprises generating a base call for a family among the families at a genetic locus of a plurality of genetic loci in the one or more reference sequences.

### Claim 48 (depends on 47)

The method of claim 47, further comprising measuring a frequency of one or more bases called at the locus from among a plurality of families.

### Claim 49 (depends on 31)

The method of claim 31, further comprising quantifying the number of families.

### Claim 50 (depends on 31)

The method of claim 31, wherein a SNV and a CNV are detected.

### Claim 51 (depends on 31)

The method of claim 31, wherein the double-stranded cell-free DNA comprises circulating tumor DNA (ctDNA).

### Claim 52 (depends on 31)

The method of claim 31, wherein the cfDNA molecules comprise between 0.1% and 1% of cfDNA molecules from a cancer genome.

### Claim 53 (depends on 31)

The method of claim 31, wherein the cfDNA molecules comprise between 0.1% and 5% of cfDNA molecules from a cancer genome.

### Claim 54 (depends on 31)

The method of claim 31, further comprising generating a report that includes a cell-free tumor mutation profile of the human subject based on the detection of the presence or absence of the one or more somatic genetic variants.

### Claim 55 (depends on 54)

The method of claim 54, wherein the report further includes a treatment recommendation for the human subject based on the cell-free tumor mutation profile.

### Claim 56

A method for detecting somatic genetic variants in cell-free deoxyribonucleic acid (cfDNA) molecules from a blood sample for cancer testing in a human subject, the method comprising:
(a) contacting between 1 nanogram (ng) to 100 ng of cfDNA molecules derived from the blood sample with at least an 80× molar excess of adapters relative to the plurality of cfDNA molecules to attach at least 20% of the cfDNA molecules to a respective pair of adapters from among the adapters, said adapters comprising a set of molecular barcodes comprising from 5 to 100 different molecular barcodes having respective molecular barcode sequences,
wherein the respective pair of adapters comprises a first adapter having a molecular barcode sequence from among the set of molecular barcodes that is attached to a first end of a cfDNA molecule from among the cfDNA molecules and a second adapter having a molecular barcode sequence from among the set of molecular barcodes that is attached to a second end of the cfDNA molecule,
wherein at least some of the tagged parent polynucleotides have an identical pair of molecular barcode sequences with respect to one another, and
wherein the molecular barcode sequences are from 5-20 base pairs in length;
(b) amplifying a plurality of the tagged parent polynucleotides to produce progeny polynucleotides;
(c) selectively enriching the progeny polynucleotides for target regions associated with cancer to produce enriched progeny polynucleotides;
(d) sequencing at least a subset of the enriched progeny polynucleotides to produce sequencing reads;
(e) aligning mappable portions of a plurality of the sequencing reads to one or more reference sequences to produce mapped sequence reads;
(f) grouping a plurality of the mapped sequence reads into families based on sequence information of the molecular barcode sequences and the beginning and end regions of the mappable portions of the mapped sequence reads; and
(g) detecting, from among the families, the presence or absence of one or more somatic genetic variants comprising a single nucleotide variation (SNV), an insertion or deletion (indel), a copy number variation (CNV), or a gene fusion.

### Claim 57 (depends on 56)

The method of claim 56, wherein said contacting comprises blunt-end ligation.

### Claim 58 (depends on 56)

The method of claim 56, wherein said contacting comprises sticky-end ligation.

### Claim 59 (depends on 56)

The method of claim 56, wherein at least 40% of the cfDNA molecules are tagged with a corresponding adapter pair.

### Claim 60 (depends on 56)

The method of claim 56, wherein (a) comprises using at least a 100× molar excess of adapters comprising the set of molecular barcodes relative to the plurality of cfDNA molecules.
